141 related articles for article (PubMed ID: 30288348)
1. The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma.
Awwad MHS; Kriegsmann K; Plaumann J; Benn M; Hillengass J; Raab MS; Bertsch U; Munder M; Weisel K; Salwender HJ; Hänel M; Fenk R; Dürig J; Müller-Tidow C; Goldschmidt H; Hundemer M
Oncoimmunology; 2018; 7(10):e1486356. PubMed ID: 30288348
[No Abstract] [Full Text] [Related]
2. IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).
Krönke J; Kuchenbauer F; Kull M; Teleanu V; Bullinger L; Bunjes D; Greiner A; Kolmus S; Köpff S; Schreder M; Mügge LO; Straka C; Engelhardt M; Döhner H; Einsele H; Bassermann F; Bargou R; Knop S; Langer C
Leukemia; 2017 Jun; 31(6):1363-1367. PubMed ID: 28017969
[TBL] [Abstract][Full Text] [Related]
3. Development of Label-Free Impedimetric Immunosensors for IKZF1 and IKZF3 Femtomolar Detection for Monitoring Multiple Myeloma Patients Treated with Lenalidomide.
Abdulkarim H; Zourob M; Siaj M
Sci Rep; 2020 Jun; 10(1):10424. PubMed ID: 32591583
[TBL] [Abstract][Full Text] [Related]
4. Baicalein Inhibits Proliferation of Myeloma U266 Cells by Downregulating IKZF1 and IKZF3.
Liu XP; He L; Zhang QP; Zeng XT; Liu SQ
Med Sci Monit; 2018 May; 24():2809-2817. PubMed ID: 29729093
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.
Krönke J; Udeshi ND; Narla A; Grauman P; Hurst SN; McConkey M; Svinkina T; Heckl D; Comer E; Li X; Ciarlo C; Hartman E; Munshi N; Schenone M; Schreiber SL; Carr SA; Ebert BL
Science; 2014 Jan; 343(6168):301-5. PubMed ID: 24292625
[TBL] [Abstract][Full Text] [Related]
6. Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.
Zheng J; Sha Y; Roof L; Foreman O; Lazarchick J; Venkta JK; Kozlowski C; Gasparetto C; Chao N; Ebens A; Hu J; Kang Y
Cancer Lett; 2019 Jan; 440-441():1-10. PubMed ID: 30312729
[TBL] [Abstract][Full Text] [Related]
7. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
Dimopoulos K; Fibiger Munch-Petersen H; Winther Eskelund C; Dissing Sjö L; Ralfkiaer E; Gimsing P; Grønbaek K
Leuk Lymphoma; 2019 Jan; 60(1):180-188. PubMed ID: 29718735
[TBL] [Abstract][Full Text] [Related]
8. High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide.
Pourabdollah M; Bahmanyar M; Atenafu EG; Reece D; Hou J; Chang H
J Hematol Oncol; 2016 Nov; 9(1):123. PubMed ID: 27881177
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide induces degradation of IKZF1 and IKZF3.
Krönke J; Hurst SN; Ebert BL
Oncoimmunology; 2014; 3(7):e941742. PubMed ID: 25610725
[TBL] [Abstract][Full Text] [Related]
10. IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.
Bolomsky A; Hübl W; Spada S; Müldür E; Schlangen K; Heintel D; Rocci A; Weißmann A; Fritz V; Willheim M; Zojer N; Palumbo A; Ludwig H
Am J Hematol; 2017 Mar; 92(3):269-278. PubMed ID: 28052520
[TBL] [Abstract][Full Text] [Related]
11. c-FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myeloma.
Osada N; Kikuchi J; Iha H; Yasui H; Ikeda S; Takahashi N; Furukawa Y
Clin Transl Med; 2023 Aug; 13(8):e1364. PubMed ID: 37581569
[TBL] [Abstract][Full Text] [Related]
12. Transcription factor IKZF1 is degraded during the apoptosis of multiple myeloma cells induced by kinase inhibition.
Liu Y; He X; Sui Y; Yu R; Xu G
FEBS Lett; 2015 Aug; 589(17):2233-40. PubMed ID: 26183205
[TBL] [Abstract][Full Text] [Related]
13. New mechanism of lenalidomide activity.
Keevan J; Figg WD
Cancer Biol Ther; 2014 Aug; 15(8):968-9. PubMed ID: 24840055
[TBL] [Abstract][Full Text] [Related]
14. Novel IKZF3 transcriptomic signature correlates with positive outcomes of skin cutaneous melanoma: A pan-cancer analysis.
Yang LK; Lin CX; Li SH; Liang JJ; Xiao LL; Xie GH; Liu HW; Liao X
Front Genet; 2022; 13():1036402. PubMed ID: 36353107
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU.1 up-regulation in myeloma cells.
Endo S; Amano M; Nishimura N; Ueno N; Ueno S; Yuki H; Fujiwara S; Wada N; Hirata S; Hata H; Mitsuya H; Okuno Y
Biochem Biophys Res Commun; 2016 Jan; 469(2):236-42. PubMed ID: 26657848
[TBL] [Abstract][Full Text] [Related]
16. Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients.
Kriegsmann K; Baertsch MA; Awwad MHS; Merz M; Hose D; Seckinger A; Jauch A; Becker N; Benner A; Raab MS; Hillengass J; Bertsch U; Dürig J; Salwender HJ; Hänel M; Fenk R; Munder M; Weisel K; Müller-Tidow C; Goldschmidt H; Hundemer M
Blood Cancer J; 2019 Jan; 9(2):13. PubMed ID: 30696815
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.
Fuchs O
Cardiovasc Hematol Disord Drug Targets; 2019; 19(1):51-78. PubMed ID: 29788898
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory drugs in the treatment of multiple myeloma.
Abe Y; Ishida T
Jpn J Clin Oncol; 2019 Aug; 49(8):695-702. PubMed ID: 31187860
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide potentiates sensitivity of multiple myeloma cells to lenalidomide by upregulating cereblon expression levels.
Jian Y; Gao W; Geng C; Zhou H; Leng Y; Li Y; Chen W
Oncol Lett; 2017 Sep; 14(3):3243-3248. PubMed ID: 28927072
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.
Holstein SA; McCarthy PL
Drugs; 2017 Apr; 77(5):505-520. PubMed ID: 28205024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
